Ignite Proteomics Announces Collaboration with Inova Health on a Biomarker Study for Late-Stage Cancers
Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference
Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay
Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response
IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies
IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1)
IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology
IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors
IMAC Holdings Announces Leadership Succession
IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business
IMAC Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements
IMAC Holdings, Inc. Announces 1-for-30 Reverse Stock Split
If You Can Only Buy One Penny Stock, It Better Be One of These 3 Names
IMAC Holdings Announces $4.3 Million Private Placement of Convertible Preferred Stock and Warrants Priced at the Market
Imac Holdings (IMAC) Receives a New Rating from Ascendiant